A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2013
At a glance
- Drugs BI 671800 (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- 04 Sep 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met, as reported in ERS abstract.
- 04 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History